Could a daily shot slow PSP? new study tests long-term safety

NCT ID NCT06235775

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety of a daily injection called GV1001 in people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and balance. It included 67 patients who had already completed a previous GV1001 study. Researchers monitored side effects and lab results over 12 months to see if the drug remains safe for extended use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROGRESSIVE SUPRANUCLEAR PALSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

progressive supranuclear palsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kyung Hee University Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul Metropolitan Government Seoul National University Boramae Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Seoul National University Hospital

    Seoul, South Korea